Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.i3, a global life sciences services company and subsidiary of Ingenix, has acquired ChinaGate, a contract research organisation (CRO) that provides product-development regulatory services for pharmaceutical, medical device and biotechnology companies looking to enter and access the Chinese market.
Subscribe to our email newsletter
i3’s customers are expected to benefit from ChinaGate’s expertise in overseeing clinical trials, submitting filings, obtaining licenses and navigating the regulatory process. ChinaGate’s customers will gain access to development, data and commercialisation services through i3’s global reach and capabilities that will help facilitate greater access to global markets.
As a subsidiary of Ingenix, i3 offers systems, information, training, learning and development, and enabling technologies.
Reportedly, ChinaGate executive team, led by Chiu and managing director Janice Ma, will continue in their roles as ChinaGate integrates with i3’s Clinical Development Services group.
Glenn Bilawsky, CEO of i3, said: “ChinaGate’s experience with the SFDA and understanding of the Chinese regulatory process will be invaluable to the services we deliver to our customers. With its reputation for specialisation and quality, ChinaGate will enhance i3’s ability to help our customers expand and sustain their business in the important Chinese market.”
Joyce Chiu, CEO of ChinaGate, said: “Combining i3’s and ChinaGate’s knowledge, experience and expertise will enable us to offer clients more comprehensive services and continued results in one of pharma and medical-device markets. We look forward to becoming part of i3.”